论文信息 - Long-term outcome of entecavir therapy in chronic hepatitis B with cirrhosis. - 字舞流文

Long-term outcome of entecavir therapy in chronic hepatitis B with cirrhosis.

[1] Wukui Cao,et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2] M. Manns,et al. Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[3] Y. Liaw. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift , 2019, Hepatology International.

[4] Y. Liaw,et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.

[5] T. Berg,et al. Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B , 2018, Hepatology.

[6] S. Lee,et al. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir , 2018, The American Journal of Gastroenterology.

[7] A. Lok,et al. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study , 2016, Alimentary pharmacology & therapeutics.